PubMed=19449367; DOI=10.1002/path.2564
Snyder E.L., Sandstrom D.J., Law K., Fiore C., Sicinska E.T., Brito J., Bailey D., Fletcher J.A., Loda M., Rodig S.J., Dal Cin P.S., Fletcher C.D.M.
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme.
J. Pathol. 218:292-300(2009)

PubMed=21930930; DOI=10.1073/pnas.1106127108; PMCID=PMC3182699
Gutierrez A.S., Snyder E.L., Marino-Enriquez A., Zhang Y.-X., Sioletic S., Kozakewich E., Grebliunaite R., Ou W.-B., Sicinska E.T., Raut C.P., Demetri G.D., Perez-Atayde A.R., Wagner A.J., Fletcher J.A., Fletcher C.D.M., Look A.T.
Aberrant AKT activation drives well-differentiated liposarcoma.
Proc. Natl. Acad. Sci. U.S.A. 108:16386-16391(2011)

PubMed=26643872; DOI=10.18632/oncotarget.6464; PMCID=PMC4767443
Kanojia D., Nagata Y., Garg M., Lee D.H., Sato A., Yoshida K., Sato Y., Sanada M., Mayakonda A., Bartenhagen C., Klein H.-U., Doan N.B., Said J.W., Mohith S., Gunasekar S., Shiraishi Y., Chiba K., Tanaka H., Miyano S., Myklebost O., Yang H.H., Dugas M., Meza-Zepeda L.A., Silberman A.W., Forscher C., Tyner J.W., Ogawa S., Koeffler H.P.
Genomic landscape of liposarcoma.
Oncotarget 6:42429-42444(2015)